Enovis Corporation (ENOV)
Enovis Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Enovis Corporation (ENOV) is a Medical - Devices company based in US with a market capitalization of $1.3B. Revenue grew 6.7% year-over-year and the company generated $19.9M in free cash flow. This page tracks ENOV's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 7.37K employees · IPO May 8, 2008
Valuation
Valuation & price
$24.29as of May 17, 2026· -32.4% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.88
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$1.3B
Market cap
6.7%
Revenue growth (YoY)
59.8%
Gross margin
$19.9M
Free cash flow (USD)
$1.3B
Net debt
2.7%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
4
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider buyJun 16, 2026Filing
Insider Buy $21KEngert Oliver · Chief Administrative Officer · $20.9K
- Insider buyJun 15, 2026Filing
Insider Buy $26KEngert Oliver · Chief Administrative Officer · $25.9K
- Insider buyJun 11, 2026Filing
Insider Buy $23KEngert Oliver · Chief Administrative Officer · $23K
- Insider buyJun 3, 2026Filing
Insider Buy $22KEngert Oliver · Chief Administrative Officer · $22.2K
- 8-K eventMay 19, 2026Filing
Omnibus Incentive Plan Amendment
- 8-K eventMay 7, 2026Filing
Earnings Release
- Quarterly reportMay 7, 2026Filing
10-Q Filed
Questions
Frequently asked questions
What is Enovis Corporation's market cap?
Enovis Corporation (ENOV) has a market capitalization of $1.3B.
What is ENOV's P/E ratio?
A meaningful P/E ratio is not available for ENOV — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is ENOV's price-to-book (P/B) ratio?
ENOV trades at 0.88 times book value per share.
Are insiders buying ENOV stock?
Yes — SEC Form 4 filings show 4 open-market insider buys and 0 sells at Enovis Corporation in the last 90 days.
Same arena
Related companies in Medical - Devices
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.